The Opharmic Team are extremely pleased to let you know that amongst over 650 submissions, we are selected to be on the prestigious list of Forbes Asia 100 to Watch in 2022!

​The recognition from Forbes Asia can’t come at a better time as we look forward to bringing you some big news here at Opharmic throughout the rest of 2022 and beyond.

Throughout the pandemic since 2020, Opharmic has:
  • Launched our first programme for partnership based on the novel MeticTouch platform technology for ocular induction, offering exclusive opportunities to partners by providing non-invasive delivery solutions to therapeutics at all stages of drug discovery
  • Established 5 partnerships with Pharma companies from US, EU, and Japan
  • Expanded our IP portfolio with granted patents in Japan, Korea, South Africa, Singapore, and China
  • Added 5 senior personnel with a combined 100 years of industrial experience covering tech development, regulatory affairs, quality assurance, marketing, and finance
The 100 to Watch list spotlights small companies and startups on the rise across the APAC region addressing real-world challenges with fresh thinking and innovative products and services. The selection is based on metrics such as a positive impact on the region or industry, a track record of strong revenue growth or ability to attract funding, promising business models or markets, and a persuasive story.

The announcement will be featured in the September issue of Forbes Asia.

We would like to take this opportunity to express our sincere gratitude to our investors and partners for the continued support! 
Our Investors: